• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Adam Simmons Outlines Efficacy of ALKS 3831 Across Subgroups of Patients With Schizophrenia

Video

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

Adam Simmons, director of clinical program management, Alkermes, interviewed at the American Psychiatric Association Annual Meeting, discussed the efficacy of the investigational drug ALKS 3831 (olanzapine/samidorphan) in various patient populations.

Transcript

What can the data presented at APA tell us about the effectiveness of ALKS 3831 compared with olanzapine across subgroups of patients?

In the data that we’re presenting here at the APA conference, what it is that we’ve shown is that the antipsychotic efficacy of olanzapine when combined with samidorphan is very similar across 3 different patient populations. One in patients that were treated in an outpatient basis; one in patients that were treated in an outpatient basis combined with schizophrenia and alcohol use disorder, and the third study we had looked at people who were acutely psychotic having an acute exacerbation of schizophrenia and comparing 3831 to placebo with olanzapine as a comparator. In that third study where we were specifically looking at antipsychotic efficacy, we did look at subgroups. We’re planning on presenting that data and describing it more in a manuscript that’ll be published in the future.

Related Videos
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Leslie Fish, PharmD.
Adam Colborn, JD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Sarah Bajorek, PhD, BCACP, MBA.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.